Bristol-Myers Squibb Company (BMY) on Decifer

Decifer ranks BMY number 78 of 277 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 14% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is not growing right now and profits grew 178% over the past year.
• It keeps a high share of every sale as profit, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Profits grew 178% but revenue is not growing right now, and with no stated worldview role and momentum of 16 out of 35 it stays mid pack.

The current read

The evidence on BMY lines up on the supportive side: options activity is unusually heavy with positioning leaning toward upside. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Bristol-Myers Squibb Company sits in the large-cap pharma layer of the Healthcare, Biotech & Devices story.

Read the full BMY research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.